Publicaciones en colaboración con investigadores/as de University of Ulm (63)

2023

  1. Revisiting autoimmune lymphoproliferative syndrome caused by Fas ligand mutations

    Journal of Allergy and Clinical Immunology, Vol. 151, Núm. 5, pp. 1391-1401.e7

  2. Risk factors for infections caused by carbapenem-resistant Enterobacterales: an international matched case-control-control study (EURECA)

    eClinicalMedicine, Vol. 57

2022

  1. A Systematic Review of the Current Evidence from Randomised Controlled Trials on the Impact of Medication Optimisation or Pharmacological Interventions on Quantitative Measures of Cognitive Function in Geriatric Patients

    Drugs and Aging, Vol. 39, Núm. 11, pp. 863-874

  2. Modeling the Prognostic Impact of Circulating Tumor Cells Enumeration in Metastatic Breast Cancer for Clinical Trial Design Simulation

    The oncologist, Vol. 27, Núm. 7, pp. e561-e570

  3. Partial Hydrolyzed Protein as a Protein Source for Infant Feeding: Do or Don’t?

    Nutrients, Vol. 14, Núm. 9

  4. The effects of callous-unemotional traits and aggression subtypes on amygdala activity in response to negative faces

    Psychological Medicine, Vol. 52, Núm. 3, pp. 476-484

  5. nextMONARCH Phase 2 randomized clinical trial: overall survival analysis of abemaciclib monotherapy or in combination with tamoxifen in patients with endocrine-refractory HR + , HER2– metastatic breast cancer

    Breast Cancer Research and Treatment, Vol. 195, Núm. 1, pp. 55-64

2021

  1. Abemaciclib as initial therapy for advanced breast cancer: MONARCH 3 updated results in prognostic subgroups

    npj Breast Cancer, Vol. 7, Núm. 1

  2. B-cell acute lymphoblastic leukemia in patients with chronic lymphocytic leukemia treated with lenalidomide

    Blood

  3. Correction to: Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials (European Journal of Clinical Pharmacology, (2021), 77, 1, (1-12), 10.1007/s00228-020-02951-8)

    European Journal of Clinical Pharmacology

  4. Current evidence on the impact of medication optimization or pharmacological interventions on frailty or aspects of frailty: a systematic review of randomized controlled trials

    European Journal of Clinical Pharmacology, Vol. 77, Núm. 1

  5. Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1

    Autophagy, Vol. 17, Núm. 1, pp. 1-382

  6. Heterogeneous contributions of change in population distribution of body mass index to change in obesity and underweight

    eLife, Vol. 10

  7. Inhaled nitric oxide (iNO) for preventing prematurity-related bronchopulmonary dysplasia (BPD): 7-year follow-up of the European Union Nitric Oxide (EUNO) trial

    Journal of Perinatal Medicine, Vol. 49, Núm. 1, pp. 104-110

  8. Reward and Punishment Sensitivity are Associated with Cross-disorder Traits

    Psychiatry Research, Vol. 298

  9. nextMONARCH: Abemaciclib Monotherapy or Combined With Tamoxifen for Metastatic Breast Cancer

    Clinical Breast Cancer, Vol. 21, Núm. 3, pp. 181-190.e2

2020

  1. Abemaciclib combined with endocrine therapy for the adjuvant treatment of HR1, HER22, node-positive, high-risk, early breast cancer (monarchE)

    Journal of Clinical Oncology, Vol. 38, Núm. 34, pp. 3987-3998

  2. Development and psychometric properties of the “Suicidality: Treatment Occurring in Paediatrics (STOP) Risk and Resilience Factors Scales” in adolescents

    European Child and Adolescent Psychiatry, Vol. 29, Núm. 2, pp. 153-165

  3. Executive functioning and emotion recognition in youth with oppositional defiant disorder and/or conduct disorder

    World Journal of Biological Psychiatry, Vol. 21, Núm. 7, pp. 539-551

  4. Psychosocial risk factors for suicidality in children and adolescents

    European Child and Adolescent Psychiatry, Vol. 29, Núm. 6, pp. 759-776